This review article highlights treatment strategies to selectively target BRCA-proficient cancers by modulating PARP activity that alters PARP binding, PAR and NAD+ levels to induce tumor-selective cell death using predictive biomarkers for therapeutic response. The gene discussed is PARP1; the disease is neoplasm.